BioCorRx Inc.
BICX
$0.3859
$0.059918.37%
| Weiss Ratings | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -1.06 | |||
| Price History | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 18.37% | |||
| 30-Day Total Return | -26.50% | |||
| 60-Day Total Return | -1.05% | |||
| 90-Day Total Return | 28.63% | |||
| Year to Date Total Return | 1.55% | |||
| 1-Year Total Return | -61.22% | |||
| 2-Year Total Return | -75.18% | |||
| 3-Year Total Return | -90.11% | |||
| 5-Year Total Return | -83.92% | |||
| 52-Week High % Change | -78.27% | |||
| 52-Week Low % Change | 15.60% | |||
| Price | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.50 | |||
| 52-Week Low Price | $0.28 | |||
| 52-Week Low Price (Date) | Aug 12, 2024 | |||
| 52-Week High Price (Date) | Apr 09, 2024 | |||
| Valuation | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.27M | |||
| Enterprise Value | 6.90M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.52 | |||
| Earnings Per Share Growth | 5.44% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 135.83 | |||
| Price/Book (Q) | -0.31 | |||
| Enterprise Value/Revenue (TTM) | 260.52 | |||
| Price | $0.39 | |||
| Enterprise Value/EBITDA (TTM) | -1.44 | |||
| Enterprise Value/EBIT | -1.43 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 10.91M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 714 462 4880 | |||
| Address | 2390 East Orangewood Avenue Anaheim, CA 92806 | |||
| Website | www.biocorrx.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -18,190.56% | |||
| Profit Margin | -18,528.30% | |||
| Management Effectiveness | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -511.51% | |||
| Return on Equity | -- | |||
| Income Statement | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 26.50K | |||
| Total Revenue (TTM) | 26.50K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 11.90K | |||
| EBITDA (TTM) | -4.79M | |||
| EBIT (TTM) | -4.82M | |||
| Net Income (TTM) | -4.91M | |||
| Net Income Avl. to Common (TTM) | -4.91M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -74.45% | |||
| EPS Diluted (TTM) | -0.52 | |||
| EPS Diluted Growth (Q YOY) | -34.38% | |||
| Balance Sheet | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 100.00 | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 353.10K | |||
| Total Preferred Equity (Q) | 0.02 | |||
| Total Equity (Q) | -12.00M | |||
| Current Ratio (Q) | 0.043 | |||
| Book Value Per Share (Q) | -$1.06 | |||
| Total Assets (Q) | 643.60K | |||
| Total Current Liabilities (Q) | 8.22M | |||
| Total Debt (Q) | 2.78M | |||
| Total Liabilities (Q) | 12.65M | |||
| Total Common Equity (Q) | -11.85M | |||
| Cash Flow | BICX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 1.23M | |||
| Net Change in Cash (TTM) | -156.30K | |||
| Levered Free Cash Flow (TTM) | -1.45M | |||
| Cash from Operations (TTM) | -1.38M | |||
